BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/11/2026 3:41:45 AM | Browse: 1 | Download: 1
 |
Received |
|
2025-09-18 02:18 |
|
Peer-Review Started |
|
2025-09-18 02:18 |
|
First Decision by Editorial Office Director |
|
2025-10-21 07:29 |
|
Return for Revision |
|
2025-10-21 07:29 |
|
Revised |
|
2025-10-21 13:44 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-22 02:32 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-22 08:58 |
|
Articles in Press |
|
2026-01-22 08:58 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-02-04 00:41 |
|
Publish the Manuscript Online |
|
2026-02-11 03:41 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Risankizumab redefines Crohn’s treatment after ustekinumab failure
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Felix Pius Omullo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Felix Pius Omullo, Department of Medical Services, Equity Afya, Kiharu Township, Lodwar 399-30500, Turkana, Kenya. piuskirasia@gmail.com |
| Key Words |
Crohn disease; Ustekinumab; Risankizumab; Interleukin-23; Drug substitution; Treatment failure; Secondary loss of response; Biological therapy |
| Core Tip |
Emerging real-world data indicate that risankizumab may induce high rates of clinical and biomarker remission after ustekinumab failure in Crohn’s disease. These findings challenge the traditional cross-class switching paradigm and suggest potential for sequential, increasingly specific interleukin-23 pathway blockade. While mechanistically plausible, the evidence remains preliminary from single-center studies. Balanced interpretation, validation in larger diverse cohorts, and rigorous cost-effectiveness analyses are needed before revising global treatment algorithms. |
| Publish Date |
2026-02-11 03:41 |
| Citation |
Omullo FP. Risankizumab redefines Crohn’s treatment after ustekinumab failure. World J Gastrointest Pharmacol Ther 2026; 17(1): 114412 |
| URL |
https://www.wjgnet.com/2150-5349/full/v17/i1/114412.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v17.i1.114412 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
